Arnatar Therapeutics

Arnatar Therapeutics is an emerging, pre-clinical biotech pioneering a dual-modality RNA therapeutics platform. Its core innovation, the DARGER™ platform, uniquely combines potent siRNA for gene silencing with a novel ASO technology (ACT-UP1) for targeted gene upregulation, addressing both gain-of-function and loss-of-function diseases. The company is building a pipeline focused on cardiometabolic, liver, CNS, and kidney disorders, aiming to create first- and best-in-class therapies where current options are inadequate. As a private, pre-revenue entity, Arnatar's success hinges on validating its novel upregulation technology and advancing its pipeline into clinical trials.

DARGER™ Platform: A dual-modality RNA discovery engine combining super-active siRNA for gene silencing with ACT-UP1, a novel ASO-based technology for gene upregulation via translation enhancement. Supported by AI-powered oligo design and a proprietary GalNAc delivery system.

Arnatar competes in the oligonucleotide space with giants like Alnylam (RNAi), Ionis, and Biogen (ASOs) in gene silencing. Its upregulation approach faces potential competition from gene therapy companies and other novel modality startups. Its success hinges on demonstrating superior efficacy or a unique mechanism (ACT-UP1) compared to existing RNA platforms.